erlotinib

Ligand id: 4920

Name: erlotinib

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: erlotinib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 10
Topological polar surface area 74.73
Molecular weight 393.17
XLogP 3.14
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
Approved drug? Yes (FDA (2004), EMA (2005))
IUPAC Name
N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
International Nonproprietary Names
INN number INN
8133 erlotinib
Synonyms
NSC 718781 | OSI 744 | OSI-774 | R 1415 | Tarceva®
Database Links
CAS Registry No. 183321-74-6
ChEBI CHEBI:114785
ChEMBL Ligand CHEMBL553
DrugBank Ligand DB00530
PubChem CID 176870
RCSB PDB Ligand AQ4
Search Google for chemical match using the InChIKey AAKJLRGGTJKAMG-UHFFFAOYSA-N
Search Google for chemicals with the same backbone AAKJLRGGTJKAMG
Search PubMed clinical trials erlotinib
Search PubMed titles erlotinib
Search PubMed titles/abstracts erlotinib
Search UniChem for chemical match using the InChIKey AAKJLRGGTJKAMG-UHFFFAOYSA-N
Search UniChem for chemicals with the same backbone AAKJLRGGTJKAMG
SynPHARM 81179 (in complex with epidermal growth factor receptor)
79526 (in complex with epidermal growth factor receptor)
Wikipedia Erlotinib
Comments
Erlotinib is a clinically approved type-1 inhibitor of the epidermal growth factor receptor (EGFR) receptor tyrosine kinase. This drug shows some selectivity for EGFR exon 19 deletion or exon 21 L858R mutations over the wild type receptor.
Subsequent studies have shown erlotinib to be a potent inhibitor of JAK2V617F activity. JAK2V617F, a mutant from of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. Study suggests that erlotinib may be used for treatment of JAK2V617F-positive PV and other myeloproliferative disorders. Specificity of inhibition with regard to other tyrosine kinase receptors remains to be fully characterized. Erlotinib is a Type-1 kinase inhibitor.